Extracorporeal Immunoadsorbents for Specific Extraction of Circulating Immune Reactants

  • David S. Terman
  • George Buffaloe


Considerable evidence has accumulated to substantiate the role of immune reactants in many experimental and human diseases.(1,2) Therapy for many of these immunologically mediated diseases has been dependent upon the use of pharmacologic agents that widely and non-specifically suppress host immunity leading to numerous undesirable effects.(3) In addition, there has been an increasing awareness of the etiologic factors in many immunologically mediated diseases and the concomitant development of many sensitive radioimmunological techniques to measure them. Therefore, we have focused our attention on a specific therapeutic measure, i.e., the development of solid phase immunoadsorbents to specifically remove pathogenic immune reactants from the circulation. For this purpose we have developed several immunoadsorbents consisting of immobilized antigens, antibodies and enzymes. When placed in an extracorporeal circuit, these immunoadsorbents have shown a capacity to specifically extract or hydrolyze immune reactants in the circulation with no demonstrable release of immobilized substances and no significant immediate or long-range toxicity to the host.


Systemic Lupus Erythematosus Collodion Membrane Bovine Serum Albumin Binding Pathogenic Immune Reactant Extracorporeal Circulation System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cochrane, C.C., and D. Koffler. 1973. Immune complex disease in experimental animals and man. Adv. Immunol. 16:185.PubMedCrossRefGoogle Scholar
  2. 2.
    Vaughan, J.H. 1971. Autoallergic diseases: concepts and general considerations. Immunological Diseases. 2:987.Google Scholar
  3. 3.
    Decker, J.L., Bertino, J.R., Hurd, E.R. & Steinberg, A.D., 1973. Cytotoxic drugs in rheumatic diseases. Arth. and Rheum. 16:79.CrossRefGoogle Scholar
  4. 4.
    Terman, D.S., Petty, D., Pefley, C., Buffaloe, G. Specific removal of circulating antibody by antigen immobilized in collodion-charcoal. Clin. Exp. Immunol. In Press.Google Scholar
  5. 5.
    Terman, D.S., Petty, D., Ogden, D., Pefley, C. and Buffaloe, G., 1976. Specific extraction of antigen in vivo by extracorporeal circulation over antibody immobilized Tn” collodion-charcoal. J. Immunol. 117:1971.PubMedGoogle Scholar
  6. 6.
    Terman, D.S., Petty, D., Ogden, D., Harbeck, R., Buffaloe, G., and Carr, R. 1976. Specific removal of DNA antibodies in vivo by extracorporeal circulation over DNA immobilized in coTTodion-charcoal. Clin. Immunol. Immunopathol. In Press.Google Scholar
  7. 7.
    Terman, D.S., Tavel, A., Tavel, T., Petty, D., Harbeck, R., Buffaloe, G., and Carr, R. 1976. Degradation of circulating DNA by extracorporeal circulation and nuclease immobilized on nylon microcapsules. J. Clin. Invest. 57:1201.PubMedCrossRefGoogle Scholar
  8. 8.
    Terman, D.S., Tavel, T., Petty, D., Tavel, A., Harbeck, R., Buffaloe, G. and Carr, R. 1976. Specific removal of bovine serum albumin (BSA) antibodies by extracorporeal circulation over BSA immobilized in nylon microcapsules. J. Immunol. 116: 1337.PubMedGoogle Scholar
  9. 9.
    Terman, D.S., Durante, D., Buffaloe, G. and Mcintosh, R. 1977. Attenuation of canine nephrotoxic glomerulonephritis with an extracorporeal immunoadsorbent. Scand. J. Immunol. 6:195.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • David S. Terman
    • 1
  • George Buffaloe
    • 1
  1. 1.Baylor College of MedicineHoustonUSA

Personalised recommendations